Sanjeev Deva
Overview
Explore the profile of Sanjeev Deva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jackson C, Hung T, Segelov E, Barlow P, Prenen H, McLaren B, et al.
Br J Clin Pharmacol
. 2021 May;
87(12):4670-4680.
PMID: 33960504
Aims: Paclitaxel is a widely used anti-neoplastic agent but has low oral bioavailability due to gut extrusion by P-glycoprotein (P-gp). Oral paclitaxel could be more convenient, less resource intensive, and...
12.
Ang E, Mweempwa A, Heron C, Ahn Y, Rivalland G, Ha L, et al.
J Immunother
. 2021 Jan;
44(4):162-163.
PMID: 33416262
Checkpoint inhibitor-associated myocarditis (ir-myocarditis) and myositis (ir-myositis) may occur concurrently among patients on checkpoint inhibitor immunotherapy. While cardiac-specific troponin I (cTnI) and troponin T (cTnT) are regarded to have similar...
13.
Desai J, Deva S, Lee J, Lin C, Yen C, Chao Y, et al.
J Immunother Cancer
. 2020 Jun;
8(1).
PMID: 32540858
Background: The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune...
14.
Wilson M, Mak W, Firth M, Deva S, Findlay M
N Z Med J
. 2017 Aug;
130(1460):63-72.
PMID: 28796772
Aims: Thirty-day mortality has been proposed to be a useful indicator of avoidable harm to patients from systemic anticancer therapies (SACT). As a quality assurance tool, we assessed the 30-day...
15.
Jackson C, Sharples K, Thompson P, ODonnell A, Robinson B, Perez D, et al.
BMC Cancer
. 2014 Oct;
14:737.
PMID: 25274181
Background: Dose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and...
16.
Broom R, Hinder V, Sharples K, Proctor J, Duffey S, Pollard S, et al.
Clin Genitourin Cancer
. 2014 Aug;
13(1):50-8.
PMID: 25163397
Background: Bone metastases from renal cell carcinoma (RCC) are a major cause of morbidity. Post hoc analysis has suggested that bone turnover markers can identify patients at risk of skeletal-related...
17.
Deva S, Jameson M
Cochrane Database Syst Rev
. 2012 Aug;
(8):CD007814.
PMID: 22895966
Background: Anecdotal reports of tumour regression with histamine type 2 receptor antagonists (H(2)RAs) have lead to a series of trials with this class of drug as adjuvant therapy to try...
18.
Broom R, Caldwell I, Hanning F, Fong P, Deva S, Oei P
Clin Genitourin Cancer
. 2012 Mar;
10(3):202-6.
PMID: 22440786
No abstract available.